Abstract:Colorectal cancer (CRC) ranks as the second leading cause of cancer‐related death worldwide due to its aggressive nature. After surgical resection, >50% of patients with CRC require adjuvant therapy. As a result, eradicating cancer cells with medications is a promising method to treat patients with CRC. In the present study, a novel compound was synthesized, which was termed compound 225#. The inhibitory activity of compound 225# against CRC was determined by MTT assay, EdU fluorescence labeling and colony formation assay; the effects of compound 225# on the cell cycle progression and apoptosis of CRC cells were detected by flow cytometry and western blotting; and the changes in autophagic flux after the administration of compound 225# were detected using the double fluorescence fusion protein mCherry‐GFP‐LC3B and western blotting. The results demonstrated that compound 225# exhibited antiproliferative properties, inhibiting the proliferation and expansion of CRC cell lines in a time‐ and dose‐dependent manner. Furthermore, compound 225# triggered G 2 /M cell cycle arrest by influencing the expression of cell cycle regulators, such as CDK1, cyclin A1 and cyclin B1, which is also closely related to the activation of DNA damage pathways. The cleavage of PARP and increased protein expression levels of PUMA suggested that apoptosis was triggered after treatment with compound 225#. Moreover, the increase in LC3‐II expression and stimulation of autophagic flux indicated the activation of an autophagy pathway. Notably, compound 225# induced autophagy, which was associated with endoplasmic reticulum (ER) stress. In accordance with the in vitro findings, the in vivo results demonstrated that compound 225# effectively inhibited the growth of HCT116 tumors in mice without causing any changes in their body weight. Collectively, the present results demonstrated that compound 225# not only inhibited proliferation and promoted G 2 /M‐phase cell cycle arrest and apoptosis, but also initiated cytoprotective autophagy in CRC cells by activating ER stress pathways. Taken together, these findings provide an experimental basis for the evaluation of compound 225# as a novel potential medication for CRC treatment.

Induction of Apoptosis and Suppression of ERCC1 Expression by the Potent Amonafide Analogue 8-C in Human Colorectal Carcinoma Cells.

8-Methoxyflindersine-Induced Apoptosis and Cell Cycle Disorder Involving MAPK Signaling Activation in Human Colorectal Cancer Cells

Identification of (S)-1-(2-(2,4-difluorophenyl)-4-oxothiazolidin-3-yl)-3-(4-((7-(3-(4-ethylpiperazin-1-yl)propoxy)-6-methoxyquinolin-4-yl)oxy)-3,5-difluorophenyl)urea as a potential anti-colorectal cancer agent

A Benzimidazole-Based N-Heterocyclic Carbene Derivative Exhibits Potent Antiproliferative and Apoptotic Effects against Colorectal Cancer

Antiproliferative Evaluation of Novel 4-Imidazolidinone Derivatives as Anticancer Agent Which Triggers ROS-Dependent Apoptosis in Colorectal Cancer Cell

Induction of Mitotic Arrest and Apoptosis by a Novel Synthetic Quinolone Analogue, CWC-8, Via Intrinsic and Extrinsic Apoptotic Pathways in Human Osteogenic Sarcoma U-2 OS Cells.

Exposure of CCRF‐CEM Cells to Acridone Derivative 8a Triggers Tumor Death Via Multiple Mechanisms

Combing Metabolomics with Bioanalysis Methods to Study the Antitumor Mechanism of the New Acridone Derivative 8q on CCRF-CEM Cells: 8q Induced Mitochondrial-Mediated Apoptosis and Targeted the PI3K/AKT/FOXO1 Pathway.

New Benzimidazole Acridine Derivative Induces Human Colon Cancer Cell Apoptosis in Vitro Via the ROS-JNK Signaling Pathway

Biological Evaluation of 8-Methoxy-2,5-dimethyl-5H-indolo[2,3-b] Quinoline as a Potential Antitumor Agent via PI3K/AKT/mTOR Signaling

Biological Evaluation of 8-Methoxy-2,5-dimethyl-5H-indolo[2,3-b] Quinoline as a Potential Antitumor Agent via PI3K/AKT/mTOR Signaling.

Compound 225# inhibits the proliferation of human colorectal cancer cells by promoting cell cycle arrest and apoptosis induction

Euxanthone suppresses tumor growth and metastasis in colorectal cancer via targeting CIP2A/PP2A pathway

N ‐allyl quinoxaline derivative exhibited potent and selective cytotoxicity through EGFR/VEGFR‐mediated apoptosis: In vitro and in vivo studies

CQ Synergistically Sensitizes Human Colorectal Cancer Cells to SN-38/CPT-11 Through Lysosomal and Mitochondrial Apoptotic Pathway Via P53-Ros Cross-Talk.

Preparation and Anti-Colon Cancer Effect of a Novel Curcumin Analogue (CA8): in Vivo and in Vitro Evaluation

The Anthraquinone Derivative C2 Enhances Oxaliplatin-Induced Cell Death and Triggers Autophagy via the PI3K/AKT/mTOR Pathway

8-Acetonyldihydronitidine Inhibits the Proliferation of Human Colorectal Cancer Cells Via Activation of P53

HZ08, a Great Regulator to Reverse Multidrug Resistance Via Cycle Arrest and Apoptosis Sensitization in MCF-7/ADM

Enhanced Chemosensitivity to CPT-11 in Colorectal Carcinoma Xenografts by Small Hairpin RNA Interference Targeting PLK1.

Quercetin Enhances 5-fluorouracil Sensitivity by Regulating the Autophagic Flux and Inducing Drp-1 Mediated Mitochondrial Fragmentation in Colorectal Cancer Cells